{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T07:50:56Z","timestamp":1777535456518,"version":"3.51.4"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T00:00:00Z","timestamp":1540339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T00:00:00Z","timestamp":1540339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Impairment of the ubiquitin proteasome system has been implicated in Parkinson\u2019s disease. We used positron emission tomography to investigate longitudinal effects of chronic intracerebroventricular exposure to the proteasome inhibitor lactacystin on monoaminergic projections and neuroinflammation. G\u00f6ttingen minipigs were implanted in the cisterna magna with a catheter connected to a subcutaneous injection port. Minipigs were imaged at baseline and after cumulative doses of 200 and 400\u2009\u03bcg lactacystin, respectively. Main radioligands included [<jats:sup>11<\/jats:sup>C]-DTBZ (vesicular monoamine transporter type 2) and [<jats:sup>11<\/jats:sup>C]-yohimbine (\u03b12-adrenoceptor). [<jats:sup>11<\/jats:sup>C]-DASB (serotonin transporter) and [<jats:sup>11<\/jats:sup>C]-PK11195 (activated microglia) became available later in the study and we present their results in a smaller subset of animals for information purposes only. Striatal [<jats:sup>11<\/jats:sup>C]-DTBZ binding potentials decreased significantly by 16% after 200\u2009\u03bcg compared to baseline, but the decrease was not sustained after 400\u2009\u03bcg (n\u2009=\u20096). [<jats:sup>11<\/jats:sup>C]-yohimbine volume of distribution increased by 18\u201325% in the pons, grey matter and the thalamus after 200\u2009\u03bcg, which persisted at 400\u2009\u03bcg (n\u2009=\u20096). In the later subset of minipigs, we observed decreased [<jats:sup>11<\/jats:sup>C]-DASB (n\u2009=\u20095) and increased [<jats:sup>11<\/jats:sup>C]-PK11195 (n\u2009=\u20093) uptake after 200\u2009\u03bcg. These changes may mimic monoaminergic changes and compensatory responses in early Parkinson\u2019s disease.<\/jats:p>","DOI":"10.1038\/s41598-018-34084-5","type":"journal-article","created":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T11:37:26Z","timestamp":1539862646000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Longitudinal monoaminergic PET imaging of chronic proteasome inhibition in minipigs"],"prefix":"10.1038","volume":"8","author":[{"given":"Thea P.","family":"Lillethorup","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas N.","family":"Glud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aage K. O.","family":"Alstrup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ove","family":"Noer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik H. T.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna C.","family":"Schacht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Landeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deniz","family":"Kirik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dariusz","family":"Orlowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens Christian H.","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doris J.","family":"Doudet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7371-8713","authenticated-orcid":false,"given":"Anne M.","family":"Landau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,24]]},"reference":[{"key":"34084_CR1","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord 30, 1591\u20131601, https:\/\/doi.org\/10.1002\/mds.26424 (2015).","journal-title":"Mov Disord"},{"key":"34084_CR2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S1474-4422(06)70373-8","volume":"5","author":"KR Chaudhuri","year":"2006","unstructured":"Chaudhuri, K. R., Healy, D. G. & Schapira, A. H. Non-motor symptoms of Parkinson\u2019s disease: diagnosis and management. Lancet Neurol 5, 235\u2013245, https:\/\/doi.org\/10.1016\/S1474-4422(06)70373-8 (2006).","journal-title":"Lancet Neurol"},{"key":"34084_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak, H. et al. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging 24, 197\u2013211 (2003).","journal-title":"Neurobiol Aging"},{"issue":"2","key":"34084_CR4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/ana.24859","volume":"81","author":"Gennaro Pagano","year":"2017","unstructured":"Pagano, G., Niccolini, F., Fusar-Poli, P. & Politis, M. Serotonin transporter in Parkinson\u2019s disease: A meta-analysis of positron emission tomography studies. Ann Neurol 81, 171\u2013180, https:\/\/doi.org\/10.1002\/ana.24859 (2017).","journal-title":"Annals of Neurology"},{"key":"34084_CR5","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1093\/brain\/awq268","volume":"133","author":"N Pavese","year":"2010","unstructured":"Pavese, N., Metta, V., Bose, S. K., Chaudhuri, K. R. & Brooks, D. J. Fatigue in Parkinson\u2019s disease is linked to striatal and limbic serotonergic dysfunction. Brain 133, 3434\u20133443, https:\/\/doi.org\/10.1093\/brain\/awq268 (2010).","journal-title":"Brain"},{"key":"34084_CR6","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1212\/WNL.0b013e3181feb2ab","volume":"75","author":"M Politis","year":"2010","unstructured":"Politis, M. et al. Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology 75, 1920\u20131927, https:\/\/doi.org\/10.1212\/WNL.0b013e3181feb2ab (2010).","journal-title":"Neurology"},{"key":"34084_CR7","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1093\/brain\/awx348","volume":"141","author":"M Sommerauer","year":"2018","unstructured":"Sommerauer, M. et al. Evaluation of the noradrenergic system in Parkinson\u2019s disease: an 11C-MeNER PET and neuromelanin MRI study. Brain 141, 496\u2013504, https:\/\/doi.org\/10.1093\/brain\/awx348 (2018).","journal-title":"Brain"},{"key":"34084_CR8","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/j.expneurol.2004.08.021","volume":"191","author":"R Betarbet","year":"2005","unstructured":"Betarbet, R., Sherer, T. B. & Greenamyre, J. T. Ubiquitin-proteasome system and Parkinson\u2019s diseases. Exp Neurol 191, S17\u201327, https:\/\/doi.org\/10.1016\/j.expneurol.2004.08.021 (2005).","journal-title":"Exp Neurol"},{"key":"34084_CR9","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini, M. G. et al. Alpha-synuclein in Lewy bodies. Nature 388, 839\u2013840, https:\/\/doi.org\/10.1038\/42166 (1997).","journal-title":"Nature"},{"key":"34084_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/00005072-199702000-00002","volume":"56","author":"K Ii","year":"1997","unstructured":"Ii, K., Ito, H., Tanaka, K. & Hirano, A. Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly. J Neuropathol Exp Neurol 56, 125\u2013131 (1997).","journal-title":"J Neuropathol Exp Neurol"},{"key":"34084_CR11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1006\/exnr.2002.8050","volume":"179","author":"KS McNaught","year":"2003","unstructured":"McNaught, K. S., Belizaire, R., Isacson, O., Jenner, P. & Olanow, C. W. Altered proteasomal function in sporadic Parkinson\u2019s disease. Exp Neurol 179, 38\u201346 (2003).","journal-title":"Exp Neurol"},{"key":"34084_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0304-3940(00)01701-8","volume":"297","author":"KS McNaught","year":"2001","unstructured":"McNaught, K. S. & Jenner, P. Proteasomal function is impaired in substantia nigra in Parkinson\u2019s disease. Neurosci Lett 297, 191\u2013194 (2001).","journal-title":"Neurosci Lett"},{"key":"34084_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.expneurol.2013.03.021","volume":"247","author":"S Mackey","year":"2013","unstructured":"Mackey, S., Jing, Y., Flores, J., Dinelle, K. & Doudet, D. J. Direct intranigral administration of an ubiquitin proteasome system inhibitor in rat: behavior, positron emission tomography, immunohistochemistry. Exp Neurol 247, 19\u201324, https:\/\/doi.org\/10.1016\/j.expneurol.2013.03.021 (2013).","journal-title":"Exp Neurol"},{"key":"34084_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.neulet.2005.01.024","volume":"380","author":"H Miwa","year":"2005","unstructured":"Miwa, H., Kubo, T., Suzuki, A., Nishi, K. & Kondo, T. Retrograde dopaminergic neuron degeneration following intrastriatal proteasome inhibition. Neurosci Lett 380, 93\u201398, https:\/\/doi.org\/10.1016\/j.neulet.2005.01.024 (2005).","journal-title":"Neurosci Lett"},{"key":"34084_CR15","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3389\/fnbeh.2015.00068","volume":"9","author":"E Bentea","year":"2015","unstructured":"Bentea, E. et al. Nigral proteasome inhibition in mice leads to motor and non-motor deficits and increased expression of Ser129 phosphorylated alpha-synuclein. Front Behav Neurosci 9, 68, https:\/\/doi.org\/10.3389\/fnbeh.2015.00068 (2015).","journal-title":"Front Behav Neurosci"},{"key":"34084_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2202-11-1","volume":"11","author":"AC Vernon","year":"2010","unstructured":"Vernon, A. C., Johansson, S. M. & Modo, M. M. Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson\u2019s disease. BMC Neurosci 11, 1, https:\/\/doi.org\/10.1186\/1471-2202-11-1 (2010).","journal-title":"BMC Neurosci"},{"key":"34084_CR17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.bbr.2013.12.019","volume":"261","author":"J Konieczny","year":"2014","unstructured":"Konieczny, J., Czarnecka, A., Lenda, T., Kaminska, K. & Lorenc-Koci, E. Chronic L-DOPA treatment attenuates behavioral and biochemical deficits induced by unilateral lactacystin administration into the rat substantia nigra. Behav Brain Res 261, 79\u201388, https:\/\/doi.org\/10.1016\/j.bbr.2013.12.019 (2014).","journal-title":"Behav Brain Res"},{"key":"34084_CR18","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1007\/s00221-017-4962-z","volume":"235","author":"MH Savolainen","year":"2017","unstructured":"Savolainen, M. H., Albert, K., Airavaara, M. & Myohanen, T. T. Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activation and shows various phenotypes of Parkinson\u2019s disease in young and adult mouse. Exp Brain Res 235, 2189\u20132202, https:\/\/doi.org\/10.1007\/s00221-017-4962-z (2017).","journal-title":"Exp Brain Res"},{"key":"34084_CR19","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1007\/s00429-016-1327-5","volume":"222","author":"CR Bjarkam","year":"2017","unstructured":"Bjarkam, C. R., Glud, A. N., Orlowski, D., Sorensen, J. C. H. & Palomero-Gallagher, N. The telencephalon of the Gottingen minipig, cytoarchitecture and cortical surface anatomy. Brain Struct Funct 222, 2093\u20132114, https:\/\/doi.org\/10.1007\/s00429-016-1327-5 (2017).","journal-title":"Brain Struct Funct"},{"key":"34084_CR20","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.brs.2015.02.003","volume":"8","author":"AM Landau","year":"2015","unstructured":"Landau, A. M. et al. Acute Vagal Nerve Stimulation Lowers alpha2 Adrenoceptor Availability: Possible Mechanism of Therapeutic Action. Brain Stimul 8, 702\u2013707, https:\/\/doi.org\/10.1016\/j.brs.2015.02.003 (2015).","journal-title":"Brain Stimul"},{"key":"34084_CR21","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3727\/000000002783985314","volume":"11","author":"AM Dall","year":"2002","unstructured":"Dall, A. M. et al. Quantitative [18F]fluorodopa\/PET and histology of fetal mesencephalic dopaminergic grafts to the striatum of MPTP-poisoned minipigs. Cell Transplant 11, 733\u2013746 (2002).","journal-title":"Cell Transplant"},{"key":"34084_CR22","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1177\/0271678X17705260","volume":"38","author":"AM Landau","year":"2018","unstructured":"Landau, A. M. et al. Elevated dopamine D1 receptor availability in striatum of Gottingen minipigs after electroconvulsive therapy. J Cereb Blood Flow Metab 38, 881\u2013887, https:\/\/doi.org\/10.1177\/0271678X17705260 (2018).","journal-title":"J Cereb Blood Flow Metab"},{"key":"34084_CR23","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/S0140-6736(14)60041-6","volume":"384","author":"AJ Stoessl","year":"2014","unstructured":"Stoessl, A. J., Lehericy, S. & Strafella, A. P. Imaging insights into basal ganglia function, Parkinson\u2019s disease, and dystonia. Lancet 384, 532\u2013544, https:\/\/doi.org\/10.1016\/S0140-6736(14)60041-6 (2014).","journal-title":"Lancet"},{"key":"34084_CR24","first-page":"2008","volume":"47","author":"S Jakobsen","year":"2006","unstructured":"Jakobsen, S. et al. Detection of alpha2-adrenergic receptors in brain of living pig with 11C-yohimbine. J Nucl Med 47, 2008\u20132015 (2006).","journal-title":"J Nucl Med"},{"key":"34084_CR25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0079-6123(10)84005-1","volume":"184","author":"A Ulusoy","year":"2010","unstructured":"Ulusoy, A., Decressac, M., Kirik, D. & Bjorklund, A. Viral vector-mediated overexpression of alpha-synuclein as a progressive model of Parkinson\u2019s disease. Prog Brain Res 184, 89\u2013111, https:\/\/doi.org\/10.1016\/S0079-6123(10)84005-1 (2010).","journal-title":"Prog Brain Res"},{"key":"34084_CR26","doi-asserted-by":"publisher","first-page":"e0139694","DOI":"10.1371\/journal.pone.0139694","volume":"10","author":"JM Van Kampen","year":"2015","unstructured":"Van Kampen, J. M., Baranowski, D. C., Robertson, H. A., Shaw, C. A. & Kay, D. G. The Progressive BSSG Rat Model of Parkinson\u2019s: Recapitulating Multiple Key Features of the Human Disease. PLoS One 10, e0139694, https:\/\/doi.org\/10.1371\/journal.pone.0139694 (2015).","journal-title":"PLoS One"},{"key":"34084_CR27","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1523\/JNEUROSCI.2289-15.2016","volume":"36","author":"T Yamasaki","year":"2016","unstructured":"Yamasaki, T. et al. Dynamic Changes in Striatal mGluR1 But Not mGluR5 during Pathological Progression of Parkinson\u2019s Disease in Human Alpha-Synuclein A53T Transgenic Rats: A Multi-PET Imaging Study. J Neurosci 36, 375\u2013384, https:\/\/doi.org\/10.1523\/JNEUROSCI.2289-15.2016 (2016).","journal-title":"J Neurosci"},{"key":"34084_CR28","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.neuro.2006.06.006","volume":"27","author":"F Sun","year":"2006","unstructured":"Sun, F. et al. Proteasome inhibitor MG-132 induces dopaminergic degeneration in cell culture and animal models. Neurotoxicology 27, 807\u2013815, https:\/\/doi.org\/10.1016\/j.neuro.2006.06.006 (2006).","journal-title":"Neurotoxicology"},{"key":"34084_CR29","doi-asserted-by":"publisher","first-page":"8955","DOI":"10.1523\/JNEUROSCI.23-26-08955.2003","volume":"23","author":"F Fornai","year":"2003","unstructured":"Fornai, F. et al. Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J Neurosci 23, 8955\u20138966 (2003).","journal-title":"J Neurosci"},{"key":"34084_CR30","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/j.1471-4159.2010.06914.x","volume":"115","author":"W Xie","year":"2010","unstructured":"Xie, W. et al. Proteasome inhibition modeling nigral neuron degeneration in Parkinson\u2019s disease. J Neurochem 115, 188\u2013199, https:\/\/doi.org\/10.1111\/j.1471-4159.2010.06914.x (2010).","journal-title":"J Neurochem"},{"key":"34084_CR31","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.expneurol.2018.02.005","volume":"303","author":"TP Lillethorup","year":"2018","unstructured":"Lillethorup, T. P. et al. Nigrostriatal proteasome inhibition impairs dopamine neurotransmission and motor function in minipigs. Exp Neurol 303, 142\u2013152, https:\/\/doi.org\/10.1016\/j.expneurol.2018.02.005 (2018).","journal-title":"Exp Neurol"},{"key":"34084_CR32","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/mds.21306","volume":"22","author":"AM Landau","year":"2007","unstructured":"Landau, A. M., Kouassi, E., Siegrist-Johnstone, R. & Desbarats, J. Proteasome inhibitor model of Parkinson\u2019s disease in mice is confounded by neurotoxicity of the ethanol vehicle. Mov Disord 22, 403\u2013407, https:\/\/doi.org\/10.1002\/mds.21306 (2007).","journal-title":"Mov Disord"},{"key":"34084_CR33","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.brainres.2007.06.076","volume":"1168","author":"BN Mathur","year":"2007","unstructured":"Mathur, B. N., Neely, M. D., Dyllick-Brenzinger, M., Tandon, A. & Deutch, A. Y. Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration. Brain Res 1168, 83\u201389, https:\/\/doi.org\/10.1016\/j.brainres.2007.06.076 (2007).","journal-title":"Brain Res"},{"key":"34084_CR34","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/ana.20936","volume":"60","author":"KS McNaught","year":"2006","unstructured":"McNaught, K. S. & Olanow, C. W. Proteasome inhibitor-induced model of Parkinson\u2019s disease. Ann Neurol 60, 243\u2013247, https:\/\/doi.org\/10.1002\/ana.20936 (2006).","journal-title":"Ann Neurol"},{"key":"34084_CR35","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1177\/0023677214540881","volume":"48","author":"N Romagnoli","year":"2014","unstructured":"Romagnoli, N. et al. Access to cerebrospinal fluid in piglets via the cisterna magna: optimization and description of the technique. Lab Anim 48, 345\u2013348, https:\/\/doi.org\/10.1177\/0023677214540881 (2014).","journal-title":"Lab Anim"},{"key":"34084_CR36","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/j.1471-4159.2010.06918.x","volume":"115","author":"H Matsui","year":"2010","unstructured":"Matsui, H. et al. Proteasome inhibition in medaka brain induces the features of Parkinson\u2019s disease. J Neurochem 115, 178\u2013187, https:\/\/doi.org\/10.1111\/j.1471-4159.2010.06918.x (2010).","journal-title":"J Neurochem"},{"key":"34084_CR37","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1001\/jamaneurol.2014.290","volume":"71","author":"IT Hsiao","year":"2014","unstructured":"Hsiao, I. T. et al. Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography. JAMA Neurol 71, 758\u2013766, https:\/\/doi.org\/10.1001\/jamaneurol.2014.290 (2014).","journal-title":"JAMA Neurol"},{"key":"34084_CR38","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/0014-2999(95)00594-3","volume":"294","author":"T Vander Borght","year":"1995","unstructured":"Vander Borght, T., Kilbourn, M., Desmond, T., Kuhl, D. & Frey, K. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol 294, 577\u2013583 (1995).","journal-title":"Eur J Pharmacol"},{"key":"34084_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0304-3940(94)90136-8","volume":"173","author":"L Naudon","year":"1994","unstructured":"Naudon, L., Leroux-Nicollet, I. & Costentin, J. Short-term treatments with haloperidol or bromocriptine do not alter the density of the monoamine vesicular transporter in the substantia nigra. Neurosci Lett 173, 1\u20134 (1994).","journal-title":"Neurosci Lett"},{"key":"34084_CR40","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/syn.20573","volume":"62","author":"J Tong","year":"2008","unstructured":"Tong, J., Wilson, A. A., Boileau, I., Houle, S. & Kish, S. J. Dopamine modulating drugs influence striatal (+)-[11C]DTBZ binding in rats: VMAT2 binding is sensitive to changes in vesicular dopamine concentration. Synapse 62, 873\u2013876, https:\/\/doi.org\/10.1002\/syn.20573 (2008).","journal-title":"Synapse"},{"key":"34084_CR41","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/(SICI)1098-2396(199807)29:3<225::AID-SYN4>3.0.CO;2-8","volume":"29","author":"DJ Doudet","year":"1998","unstructured":"Doudet, D. J. et al. 6-[18F]Fluoro-L-DOPA PET studies of the turnover of dopamine in MPTP-induced parkinsonism in monkeys. Synapse 29, 225\u2013232, 10.1002\/(SICI)1098-2396(199807)29:3<225::AID-SYN4>3.0.CO;2-8 (1998).","journal-title":"Synapse"},{"key":"34084_CR42","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/00004647-200202000-00011","volume":"22","author":"V Sossi","year":"2002","unstructured":"Sossi, V. et al. Increase in dopamine turnover occurs early in Parkinson\u2019s disease: evidence from a new modeling approach to PET 18 F-fluorodopa data. J Cereb Blood Flow Metab 22, 232\u2013239, https:\/\/doi.org\/10.1097\/00004647-200202000-00011 (2002).","journal-title":"J Cereb Blood Flow Metab"},{"key":"34084_CR43","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1097\/01.WCB.0000126563.85360.75","volume":"24","author":"V Sossi","year":"2004","unstructured":"Sossi, V. et al. Changes of dopamine turnover in the progression of Parkinson\u2019s disease as measured by positron emission tomography: their relation to disease-compensatory mechanisms. J Cereb Blood Flow Metab 24, 869\u2013876, https:\/\/doi.org\/10.1097\/01.WCB.0000126563.85360.75 (2004).","journal-title":"J Cereb Blood Flow Metab"},{"key":"34084_CR44","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1034\/j.1600-0404.2001.103005309.x","volume":"103","author":"P Cumming","year":"2001","unstructured":"Cumming, P. et al. Normalization of markers for dopamine innervation in striatum of MPTP-lesioned miniature pigs with intrastriatal grafts. Acta Neurol Scand 103, 309\u2013315 (2001).","journal-title":"Acta Neurol Scand"},{"key":"34084_CR45","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/0306-4522(95)00571-4","volume":"72","author":"CS Lee","year":"1996","unstructured":"Lee, C. S., Sauer, H. & Bjorklund, A. Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by instrastriatal 6-hydroxydopamine in the rat. Neuroscience 72, 641\u2013653 (1996).","journal-title":"Neuroscience"},{"issue":"Pt 5","key":"34084_CR46","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1093\/brain\/114.5.2283","volume":"114","author":"JM Fearnley","year":"1991","unstructured":"Fearnley, J. M. & Lees, A. J. Ageing and Parkinson\u2019s disease: substantia nigra regional selectivity. Brain 114(Pt 5), 2283\u20132301 (1991).","journal-title":"Brain"},{"key":"34084_CR47","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.expneurol.2017.10.002","volume":"298","author":"J Blesa","year":"2017","unstructured":"Blesa, J. et al. Compensatory mechanisms in Parkinson\u2019s disease: Circuits adaptations and role in disease modification. Exp Neurol 298, 148\u2013161, https:\/\/doi.org\/10.1016\/j.expneurol.2017.10.002 (2017).","journal-title":"Exp Neurol"},{"key":"34084_CR48","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/1531-8249(200004)47:4<493::AID-ANA13>3.0.CO;2-4","volume":"47","author":"CS Lee","year":"2000","unstructured":"Lee, C. S. et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson\u2019s disease. Ann Neurol 47, 493\u2013503 (2000).","journal-title":"Ann Neurol"},{"key":"34084_CR49","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/sj.jcbfm.9600599","volume":"28","author":"RL Albin","year":"2008","unstructured":"Albin, R. L. et al. Spared caudal brainstem SERT binding in early Parkinson\u2019s disease. J Cereb Blood Flow Metab 28, 441\u2013444, https:\/\/doi.org\/10.1038\/sj.jcbfm.9600599 (2008).","journal-title":"J Cereb Blood Flow Metab"},{"key":"34084_CR50","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.nbd.2010.05.028","volume":"40","author":"M Politis","year":"2010","unstructured":"Politis, M. et al. Staging of serotonergic dysfunction in Parkinson\u2019s disease: an in vivo 11C-DASB PET study. Neurobiol Dis 40, 216\u2013221, https:\/\/doi.org\/10.1016\/j.nbd.2010.05.028 (2010).","journal-title":"Neurobiol Dis"},{"key":"34084_CR51","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/j.1468-1331.2007.01727.x","volume":"14","author":"M Guttman","year":"2007","unstructured":"Guttman, M. et al. Brain serotonin transporter binding in non-depressed patients with Parkinson\u2019s disease. Eur J Neurol 14, 523\u2013528, https:\/\/doi.org\/10.1111\/j.1468-1331.2007.01727.x (2007).","journal-title":"Eur J Neurol"},{"key":"34084_CR52","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/aps.2012.203","volume":"34","author":"YF Shen","year":"2013","unstructured":"Shen, Y. F., Tang, Y., Zhang, X. J., Huang, K. X. & Le, W. D. Adaptive changes in autophagy after UPS impairment in Parkinson\u2019s disease. Acta Pharmacol Sin 34, 667\u2013673, https:\/\/doi.org\/10.1038\/aps.2012.203 (2013).","journal-title":"Acta Pharmacol Sin"},{"key":"34084_CR53","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1046\/j.1471-4159.2003.01885.x","volume":"86","author":"Q Ding","year":"2003","unstructured":"Ding, Q. et al. Characterization of chronic low-level proteasome inhibition on neural homeostasis. J Neurochem 86, 489\u2013497 (2003).","journal-title":"J Neurochem"},{"key":"34084_CR54","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1016\/j.biocel.2004.05.008","volume":"36","author":"HJ Rideout","year":"2004","unstructured":"Rideout, H. J., Lang-Rollin, I. & Stefanis, L. Involvement of macroautophagy in the dissolution of neuronal inclusions. Int J Biochem Cell Biol 36, 2551\u20132562, https:\/\/doi.org\/10.1016\/j.biocel.2004.05.008 (2004).","journal-title":"Int J Biochem Cell Biol"},{"key":"34084_CR55","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/ana.20186","volume":"56","author":"KS McNaught","year":"2004","unstructured":"McNaught, K. S., Perl, D. P., Brownell, A. L. & Olanow, C. W. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson\u2019s disease. Ann Neurol 56, 149\u2013162, https:\/\/doi.org\/10.1002\/ana.20186 (2004).","journal-title":"Ann Neurol"},{"key":"34084_CR56","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1093\/abbs\/gmp031","volume":"41","author":"L Zhang","year":"2009","unstructured":"Zhang, L., Sheng, R. & Qin, Z. The lysosome and neurodegenerative diseases. Acta Biochim Biophys Sin (Shanghai) 41, 437\u2013445 (2009).","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"34084_CR57","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/S1474-4422(07)70076-5","volume":"6","author":"M Martinez-Vicente","year":"2007","unstructured":"Martinez-Vicente, M. & Cuervo, A. M. Autophagy and neurodegeneration: when the cleaning crew goes on strike. Lancet Neurol 6, 352\u2013361, https:\/\/doi.org\/10.1016\/S1474-4422(07)70076-5 (2007).","journal-title":"Lancet Neurol"},{"key":"34084_CR58","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S0014-5793(01)03115-5","volume":"509","author":"GK Tofaris","year":"2001","unstructured":"Tofaris, G. K., Layfield, R. & Spillantini, M. G. alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett 509, 22\u201326 (2001).","journal-title":"FEBS Lett"},{"key":"34084_CR59","doi-asserted-by":"publisher","first-page":"14508","DOI":"10.1523\/JNEUROSCI.1560-11.2011","volume":"31","author":"D Ebrahimi-Fakhari","year":"2011","unstructured":"Ebrahimi-Fakhari, D. et al. Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of alpha-synuclein. J Neurosci 31, 14508\u201314520, https:\/\/doi.org\/10.1523\/JNEUROSCI.1560-11.2011 (2011).","journal-title":"J Neurosci"},{"key":"34084_CR60","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1111\/j.1471-4159.2004.02813.x","volume":"91","author":"CS Lee","year":"2004","unstructured":"Lee, C. S. et al. A proteasomal stress response: pre-treatment with proteasome inhibitors increases proteasome activity and reduces neuronal vulnerability to oxidative injury. J Neurochem 91, 996\u20131006, https:\/\/doi.org\/10.1111\/j.1471-4159.2004.02813.x (2004).","journal-title":"J Neurochem"},{"key":"34084_CR61","doi-asserted-by":"publisher","first-page":"4364","DOI":"10.1074\/jbc.M603712200","volume":"282","author":"N Yamamoto","year":"2007","unstructured":"Yamamoto, N. et al. Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease. J Biol Chem 282, 4364\u20134372, https:\/\/doi.org\/10.1074\/jbc.M603712200 (2007).","journal-title":"J Biol Chem"},{"key":"34084_CR62","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s10571-009-9402-6","volume":"29","author":"T Oshikawa","year":"2009","unstructured":"Oshikawa, T. et al. Systemic administration of proteasome inhibitor protects against MPTP neurotoxicity in mice. Cell Mol Neurobiol 29, 769\u2013777, https:\/\/doi.org\/10.1007\/s10571-009-9402-6 (2009).","journal-title":"Cell Mol Neurobiol"},{"key":"34084_CR63","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1254\/jphs.FP0040525","volume":"97","author":"M Inden","year":"2005","unstructured":"Inden, M. et al. Proteasome inhibitors protect against degeneration of nigral dopaminergic neurons in hemiparkinsonian rats. J Pharmacol Sci 97, 203\u2013211 (2005).","journal-title":"J Pharmacol Sci"},{"key":"34084_CR64","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1080\/10408440802014287","volume":"38","author":"EJ Calabrese","year":"2008","unstructured":"Calabrese, E. J. Drug therapies for stroke and traumatic brain injury often display U-shaped dose responses: occurrence, mechanisms, and clinical implications. Crit Rev Toxicol 38, 557\u2013577, https:\/\/doi.org\/10.1080\/10408440802014287 (2008).","journal-title":"Crit Rev Toxicol"},{"key":"34084_CR65","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1146\/annurev.publhealth.22.1.15","volume":"22","author":"EJ Calabrese","year":"2001","unstructured":"Calabrese, E. J. & Baldwin, L. A. U-shaped dose-responses in biology, toxicology, and public health. Annu Rev Public Health 22, 15\u201333, https:\/\/doi.org\/10.1146\/annurev.publhealth.22.1.15 (2001).","journal-title":"Annu Rev Public Health"},{"issue":"Suppl 1","key":"34084_CR66","doi-asserted-by":"publisher","first-page":"S126","DOI":"10.1002\/mds.870040514","volume":"4","author":"Y Agid","year":"1989","unstructured":"Agid, Y. et al. Biochemistry of Parkinson\u2019s disease 28 years later: a critical review. Mov Disord 4(Suppl 1), S126\u2013144 (1989).","journal-title":"Mov Disord"},{"key":"34084_CR67","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/cne.902870308","volume":"287","author":"V Chan-Palay","year":"1989","unstructured":"Chan-Palay, V. & Asan, E. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson\u2019s disease with and without dementia and depression. J Comp Neurol 287, 373\u2013392, https:\/\/doi.org\/10.1002\/cne.902870308 (1989).","journal-title":"J Comp Neurol"},{"key":"34084_CR68","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1002\/mds.26048","volume":"29","author":"AJ Espay","year":"2014","unstructured":"Espay, A. J., LeWitt, P. A. & Kaufmann, H. Norepinephrine deficiency in Parkinson\u2019s disease: the case for noradrenergic enhancement. Mov Disord 29, 1710\u20131719, https:\/\/doi.org\/10.1002\/mds.26048 (2014).","journal-title":"Mov Disord"},{"key":"34084_CR69","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2967\/jnumed.117.190975","volume":"59","author":"A Nahimi","year":"2018","unstructured":"Nahimi, A. et al. Noradrenergic Deficits in Parkinson Disease Imaged with (11)C-MeNER. J Nucl Med 59, 659\u2013664, https:\/\/doi.org\/10.2967\/jnumed.117.190975 (2018).","journal-title":"J Nucl Med"},{"key":"34084_CR70","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1007\/s11095-013-1139-8","volume":"30","author":"JA Williams","year":"2013","unstructured":"Williams, J. A., Hou, Y., Ni, H. M. & Ding, W. X. Role of intracellular calcium in proteasome inhibitor-induced endoplasmic reticulum stress, autophagy, and cell death. Pharm Res 30, 2279\u20132289, https:\/\/doi.org\/10.1007\/s11095-013-1139-8 (2013).","journal-title":"Pharm Res"},{"key":"34084_CR71","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.mcn.2015.08.012","volume":"68","author":"LA Matschke","year":"2015","unstructured":"Matschke, L. A. et al. A concerted action of L- and T-type Ca(2+) channels regulates locus coeruleus pacemaking. Mol Cell Neurosci 68, 293\u2013302, https:\/\/doi.org\/10.1016\/j.mcn.2015.08.012 (2015).","journal-title":"Mol Cell Neurosci"},{"key":"34084_CR72","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2047-9158-1-4","volume":"1","author":"PA Lewitt","year":"2012","unstructured":"Lewitt, P. A. Norepinephrine: the next therapeutics frontier for Parkinson\u2019s disease. Transl Neurodegener 1, 4, https:\/\/doi.org\/10.1186\/2047-9158-1-4 (2012).","journal-title":"Transl Neurodegener"},{"issue":"Pt A","key":"34084_CR73","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.neuropharm.2013.08.033","volume":"76","author":"TN Taylor","year":"2014","unstructured":"Taylor, T. N., Alter, S. P., Wang, M., Goldstein, D. S. & Miller, G. W. Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus. Neuropharmacology 76(Pt A), 97\u2013105, https:\/\/doi.org\/10.1016\/j.neuropharm.2013.08.033 (2014).","journal-title":"Neuropharmacology"},{"key":"34084_CR74","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.nbd.2005.08.002","volume":"21","author":"A Gerhard","year":"2006","unstructured":"Gerhard, A. et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson\u2019s disease. Neurobiol Dis 21, 404\u2013412, https:\/\/doi.org\/10.1016\/j.nbd.2005.08.002 (2006).","journal-title":"Neurobiol Dis"},{"key":"34084_CR75","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/S1474-4422(17)30173-4","volume":"16","author":"MG Stokholm","year":"2017","unstructured":"Stokholm, M. G. et al. Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. Lancet Neurol 16, 789\u2013796, https:\/\/doi.org\/10.1016\/S1474-4422(17)30173-4 (2017).","journal-title":"Lancet Neurol"},{"key":"34084_CR76","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1212\/WNL.38.8.1285","volume":"38","author":"PL McGeer","year":"1988","unstructured":"McGeer, P. L., Itagaki, S., Boyes, B. E. & McGeer, E. G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson\u2019s and Alzheimer\u2019s disease brains. Neurology 38, 1285\u20131291 (1988).","journal-title":"Neurology"},{"key":"34084_CR77","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s00401-003-0766-2","volume":"106","author":"K Imamura","year":"2003","unstructured":"Imamura, K. et al. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson\u2019s disease brains. Acta Neuropathol 106, 518\u2013526, https:\/\/doi.org\/10.1007\/s00401-003-0766-2 (2003).","journal-title":"Acta Neuropathol"},{"key":"34084_CR78","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/ana.10728","volume":"54","author":"PL McGeer","year":"2003","unstructured":"McGeer, P. L., Schwab, C., Parent, A. & Doudet, D. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann Neurol 54, 599\u2013604, https:\/\/doi.org\/10.1002\/ana.10728 (2003).","journal-title":"Ann Neurol"},{"key":"34084_CR79","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00429-013-0669-5","volume":"220","author":"IS Pienaar","year":"2015","unstructured":"Pienaar, I. S. et al. An animal model mimicking pedunculopontine nucleus cholinergic degeneration in Parkinson\u2019s disease. Brain Struct Funct 220, 479\u2013500, https:\/\/doi.org\/10.1007\/s00429-013-0669-5 (2015).","journal-title":"Brain Struct Funct"},{"key":"34084_CR80","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.drup.2010.04.003","volume":"13","author":"WK Wu","year":"2010","unstructured":"Wu, W. K. et al. Macroautophagy modulates cellular response to proteasome inhibitors in cancer therapy. Drug Resist Updat 13, 87\u201392, https:\/\/doi.org\/10.1016\/j.drup.2010.04.003 (2010).","journal-title":"Drug Resist Updat"},{"key":"34084_CR81","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.1158\/0008-5472.CAN-08-2839","volume":"69","author":"M Milani","year":"2009","unstructured":"Milani, M. et al. The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib. Cancer Res 69, 4415\u20134423, https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-2839 (2009).","journal-title":"Cancer Res"},{"key":"34084_CR82","doi-asserted-by":"crossref","first-page":"508","DOI":"10.55782\/ane-2011-1867","volume":"71","author":"AN Glud","year":"2011","unstructured":"Glud, A. N. et al. Direct MRI-guided stereotaxic viral mediated gene transfer of alpha-synuclein in the Gottingen minipig CNS. Acta Neurobiol Exp (Wars) 71, 508\u2013518 (2011).","journal-title":"Acta Neurobiol Exp (Wars)"},{"key":"34084_CR83","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/ner.12484","volume":"19","author":"AN Glud","year":"2016","unstructured":"Glud, A. N. et al. Feasibility of Three-Dimensional Placement of Human Therapeutic Stem Cells Using the Intracerebral Microinjection Instrument. Neuromodulation 19, 708\u2013716, https:\/\/doi.org\/10.1111\/ner.12484 (2016).","journal-title":"Neuromodulation"},{"key":"34084_CR84","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.3791\/2652","volume":"52","author":"KS Ettrup","year":"2011","unstructured":"Ettrup, K. S. et al. Basic surgical techniques in the Gottingen minipig: intubation, bladder catheterization, femoral vessel catheterization, and transcardial perfusion. J Vis Exp 52, 2652, https:\/\/doi.org\/10.3791\/2652 (2011).","journal-title":"J Vis Exp"},{"issue":"12","key":"34084_CR85","doi-asserted-by":"publisher","first-page":"e22060","DOI":"10.1002\/syn.22060","volume":"72","author":"Thea Pinholt Lillethorup","year":"2018","unstructured":"Pinholt Lillethorup, T. et al. In vivo Quantification of Glial Activation in Minipigs Overexpressing human alpha-synuclein. Synapse, https:\/\/doi.org\/10.1002\/syn.22060 (2018).","journal-title":"Synapse"},{"key":"34084_CR86","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1006\/nimg.2001.0910","volume":"14","author":"H Watanabe","year":"2001","unstructured":"Watanabe, H. et al. MR-based statistical atlas of the Gottingen minipig brain. Neuroimage 14, 1089\u20131096, https:\/\/doi.org\/10.1006\/nimg.2001.0910 (2001).","journal-title":"Neuroimage"},{"key":"34084_CR87","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13024-016-0125-0","volume":"11","author":"N Landeck","year":"2016","unstructured":"Landeck, N. et al. A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein. Mol Neurodegener 11, 61, https:\/\/doi.org\/10.1186\/s13024-016-0125-0 (2016).","journal-title":"Mol Neurodegener"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-34084-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-34084-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-34084-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T14:09:50Z","timestamp":1720706990000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-34084-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,24]]},"references-count":87,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["34084"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-34084-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,24]]},"assertion":[{"value":"21 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"15715"}}